Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
Want to see DWTX full AI Analyst Report?
Top Page
Dogwood Therapeutics
(NASDAQ:DWTX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▼(-52.38% Downside)
Action:Reiterated
Date:05/18/26
Overall score is pressured primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn), supported only partially by a low-debt balance sheet. Technicals add caution given the price remains below key longer-term moving averages and MACD is negative. Valuation is also a headwind because the negative P/E reflects an unprofitable profile and no dividend yield is available.
Positive Factors
Low leverage
Very low leverage and a meaningful equity base reduce near-term solvency risk and give the company financial flexibility to fund clinical programs. This balance sheet strength supports partnering, licensing discussions and execution of development milestones before revenue generation.
Negative Factors
Pre-revenue
The company remains pre-commercial with zero reported revenue, meaning no internal, recurring cash generation. Long-term viability depends on successful trial outcomes, licensing or commercial launches; absent those, the business must continually access external capital to operate.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage and a meaningful equity base reduce near-term solvency risk and give the company financial flexibility to fund clinical programs. This balance sheet strength supports partnering, licensing discussions and execution of development milestones before revenue generation.
Read all positive factors
Dogwood Therapeutics (DWTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.79M
Dividend YieldN/A
Average Volume (3M)1.54M
Price to Earnings (P/E)―
Beta (1Y)2.12
Revenue GrowthN/A
EPS Growth40.89%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.60
Shares Outstanding33,629,555
10 Day Avg. Volume77,367
30 Day Avg. Volume1,536,657
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-2.19
Enterprise Value/Market Cap-0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$13.50Price Target Upside328.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Dogwood Therapeutics Business Overview & Revenue Model
Company Description
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading thera...
How the Company Makes Money
As a clinical-stage biotechnology company, Dogwood Therapeutics does not have publicly available evidence of recurring product revenue from marketed drugs; accordingly, specific commercial revenue streams (e.g., product sales, royalties, or servic...
Dogwood Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -12.18K | 0.00 | 0.00 | 0.00 |
| EBITDA | -28.25M | -34.03M | -12.25M | -5.30M | -12.25M | -15.96M |
| Net Income | -28.32M | -34.26M | -12.35M | -5.30M | -12.25M | -15.96M |
Balance Sheet | ||||||
| Total Assets | 95.21M | 90.17M | 94.31M | 4.17M | 8.37M | 15.78M |
| Cash, Cash Equivalents and Short-Term Investments | 13.23M | 6.52M | 14.85M | 3.32M | 7.03M | 14.01M |
| Total Debt | 144.93K | 162.60K | 15.59M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 14.58M | 15.27M | 30.03M | 358.55K | 1.04M | 1.28M |
| Stockholders Equity | 80.62M | 74.90M | 64.28M | 3.81M | 7.33M | 14.50M |
Cash Flow | ||||||
| Free Cash Flow | -15.52M | -15.62M | -8.79M | -4.87M | -11.47M | -15.69M |
| Operating Cash Flow | -15.52M | -15.62M | -8.79M | -4.87M | -11.47M | -15.69M |
| Investing Cash Flow | 0.00 | 0.00 | 3.76M | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 11.20M | 7.28M | 16.70M | 1.16M | 4.49M | -97.60K |
Dogwood Therapeutics Technical Analysis
Negative
3.15
Price Trends
1.67
Negative
2.26
Negative
3.83
Negative
Market Momentum
-0.06
Positive
43.24
Neutral
37.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DWTX, the sentiment is Negative. The current price of 3.15 is above the 20-day moving average (MA) of 1.67, above the 50-day MA of 1.67, and below the 200-day MA of 3.83, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 43.24 is Neutral, neither overbought nor oversold. The STOCH value of 37.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DWTX.
Dogwood Therapeutics Risk Analysis
Dogwood Therapeutics disclosed 67 risk factors in its most recent earnings report. Dogwood Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dogwood Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $6.75M | -0.31 | -291.07% | ― | ― | 68.70% | |
45 Neutral | $51.79M | -1.82 | -35.91% | ― | ― | 40.89% | |
45 Neutral | $8.98M | -0.29 | -423.84% | ― | -8.47% | 25.61% | |
44 Neutral | $23.01M | -2.45 | >-0.01% | ― | -43.86% | 49.21% | |
44 Neutral | $17.45M | -0.09 | -83.59% | ― | ― | 19.36% | |
40 Underperform | $8.76M | -0.29 | -97.58% | ― | 78.64% | 50.70% |
* Healthcare Sector Average
DWTX
Dogwood Therapeutics
1.54
-3.25
-67.85%
MRKR
Marker Therapeutics
1.38
-0.14
-9.21%
BRTX
BioRestorative Therapies
0.35
-1.27
-78.27%
SNSE
Sensei Biotherapeutics
13.00
6.48
99.39%
BOLT
Bolt Biotherapeutics
4.56
-1.21
-20.97%
ACXP
Acurx Pharmaceuticals
1.57
-4.57
-74.43%
Dogwood Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Dogwood Therapeutics Highlights Pipeline Progress and Extended Runway
Positive
Mar 26, 2026
On March 26, 2026, Dogwood Therapeutics issued a first-quarter shareholder letter detailing significant progress across its clinical pipeline and financing. The company highlighted enrollment of 145 patients in its Phase 2b HALT-CINP study of Haln...
Private Placements and FinancingShareholder Meetings
Dogwood Therapeutics Shareholders Approve Warrant Exercise Proposal
Positive
Mar 12, 2026
On March 11, 2026, Dogwood Therapeutics held a special meeting at which shareholders representing 88.03% of the company’s voting power were present, satisfying quorum requirements and underscoring strong investor engagement. At this meeting,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.